Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older
Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years Over half of all women experience a uUTI in their lifetime, with approximately... Read more.
KBRA Assigns Preliminary Ratings to BRAVO Residential Funding Trust 2025-NQM3 (BRAVO 2025-NQM3)
NEW YORK–(BUSINESS WIRE)–#creditratingagency–KBRA assigns preliminary ratings to ten classes of mortgage-backed notes from BRAVO Residential Funding... Read more.
Watts Named on TIME’s List of America’s Top GreenTech Companies 2025
NORTH ANDOVER, Mass.–(BUSINESS WIRE)–Watts Water Technologies, Inc. (NYSE: WTS) has been named one of America’s Top GreenTech Companies 2025 by TIME.... Read more.
Loomis Sayles Celebrates 5-Year Anniversary of Growth Equity Strategies Team’s International Growth Strategy
The strategy is among a suite of equity offerings managed by Aziz V. Hamzaogullari, founder, chief investment officer and portfolio manager of the Loomis Sayles... Read more.
United Rentals Selected as One of America’s Best-Managed Companies
Company Chosen in Annual Management Top 250 List Presented by Wall Street Journal STAMFORD, Conn.–(BUSINESS WIRE)–United Rentals, Inc. (NYSE: URI), the... Read more.
Securities Fraud Investigation Into Perpetua Resources Corp. (PPTA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of Perpetua Resources Corp. (“Perpetua” or the “Company”)... Read more.
FORE Biotherapeutics to Present Two Plixorafenib Abstracts at the American Association for Cancer Research Annual Meeting 2025
PHILADELPHIA–(BUSINESS WIRE)–FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients... Read more.
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
– Presentations will highlight best- and/or first-in-class potential of four small molecule and biotherapeutic development candidates for investigation in patients... Read more.
Shadow Power Announces OpenADR 2.0b Compliance
NEW YORK–(BUSINESS WIRE)–Shadow Power, a leader in customer energy resource (CERs) management, proudly announces that its platform is now OpenADR 2.0b... Read more.
Schrödinger to Present Preclinical Data at AACR Annual Meeting
Presentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174 NEW YORK–(BUSINESS WIRE)–Schrödinger, Inc. (Nasdaq:... Read more.